The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
accepted:
22
04
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Cutaneous immune-related adverse events encompass a spectrum of dermatological manifestations, including lichenoid reactions, psoriasiform eruptions, eczematous dermatitis, immunobullous disorders, granulomatous reactions, pruritus, vitiligo, and severe cutaneous adverse reactions such as Stevens-Johnson syndrome. The conventional approach to treating high-grade or refractory cutaneous immune-related adverse events has involved high-dose systemic corticosteroids. However, their use is limited owing to the potential disruption of antitumor responses and associated complications. To address this, corticosteroid-sparing targeted immunomodulators have been explored as therapeutic alternatives. Biologic agents, commonly employed for non-cutaneous immune-related adverse events such as colitis, are increasingly recognized for their efficacy in treating various patterns of cutaneous immune-related adverse events, including psoriasiform, immunobullous, and Stevens-Johnson syndrome-like reactions. This review consolidates findings from the English-language literature, highlighting the use of biologic agents in managing diverse cutaneous immune-related adverse event patterns, also encompassing maculopapular, eczematous, and lichenoid eruptions, pruritus, and transient acantholytic dermatosis (Grover disease). Despite the established efficacy of these agents, further research is necessary to explore their long-term effects on antitumor responses.
Identifiants
pubmed: 38767827
doi: 10.1007/s40257-024-00866-z
pii: 10.1007/s40257-024-00866-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Tattersall IW, Leventhal JS. Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. Yale J Biol Med. 2020;93(1):123–32.
pubmed: 32226342
pmcid: 7087048
Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl. 1):31–9. https://doi.org/10.1007/s40257-018-0384-3 .
doi: 10.1007/s40257-018-0384-3
pubmed: 30374901
pmcid: 6244569
Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–68. https://doi.org/10.1016/j.jaad.2020.03.132 .
doi: 10.1016/j.jaad.2020.03.132
pubmed: 32454097
pmcid: 7572894
Fay CJ, Jakuboski S, McLellan B, et al. Diagnosis and management of dermatologic adverse events from systemic melanoma therapies. Am J Clin Dermatol. 2023;24(5):765–85. https://doi.org/10.1007/s40257-023-00790-8 .
doi: 10.1007/s40257-023-00790-8
pubmed: 37395930
Apalla Z, Sibaud V. Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy. Support Care Cancer. 2020;28(12):5597–9. https://doi.org/10.1007/s00520-020-05701-9 .
doi: 10.1007/s00520-020-05701-9
pubmed: 32827054
Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol. 2019;5(5):285–307. https://doi.org/10.1016/j.ijwd.2019.10.003 .
doi: 10.1016/j.ijwd.2019.10.003
pubmed: 31909148
pmcid: 6938835
Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–53. https://doi.org/10.1001/jamaoncol.2016.1051 .
doi: 10.1001/jamaoncol.2016.1051
pubmed: 27367787
Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746–58. https://doi.org/10.1200/JCO.18.02141 .
doi: 10.1200/JCO.18.02141
pubmed: 31216228
pmcid: 7001790
Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–8. https://doi.org/10.1200/JCO.2018.79.0006 .
doi: 10.1200/JCO.2018.79.0006
pubmed: 30125216
Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706–14. https://doi.org/10.1002/cncr.31629 .
doi: 10.1002/cncr.31629
pubmed: 29975414
Montfort A, Filleron T, Virazels M, et al. Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin Cancer Res. 2021;27(4):1037–47. https://doi.org/10.1158/1078-0432.CCR-20-3449 .
doi: 10.1158/1078-0432.CCR-20-3449
pubmed: 33272982
Lesage C, Longvert C, Prey S, et al. Incidence and clinical impact of anti-TNFalpha treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit Survey. J Immunother. 2019;42(5):175–9. https://doi.org/10.1097/CJI.0000000000000268 .
doi: 10.1097/CJI.0000000000000268
pubmed: 31090656
Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019;7(1):226. https://doi.org/10.1186/s40425-019-0711-0 .
doi: 10.1186/s40425-019-0711-0
pubmed: 31439050
pmcid: 6704680
Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736–45. https://doi.org/10.1016/j.annonc.2021.02.016 .
doi: 10.1016/j.annonc.2021.02.016
pubmed: 33667669
Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events: the EADV Task Force “Dermatology for cancer patients” position statement. J Eur Acad Dermatol Venereol. 2022;36(3):332–50. https://doi.org/10.1111/jdv.17855 .
doi: 10.1111/jdv.17855
pubmed: 34910332
Monsour EP, Pothen J, Balaraman R. A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report. Cureus. 2019;11(10): e5824. https://doi.org/10.7759/cureus.5824 .
doi: 10.7759/cureus.5824
pubmed: 31754559
pmcid: 6827694
Johnson D, Patel AB, Uemura MI, et al. IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res. 2019;7(6):860–5. https://doi.org/10.1158/2326-6066.CIR-18-0682 .
doi: 10.1158/2326-6066.CIR-18-0682
pubmed: 30996018
Lo JJ, Heberton MM, Pacha O, Huen AO, Patel AB. Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients. Support Care Cancer. 2022;30(2):989–94. https://doi.org/10.1007/s00520-021-06548-4 .
doi: 10.1007/s00520-021-06548-4
pubmed: 34519869
Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376(20):1989–91. https://doi.org/10.1056/NEJMc1703047 .
doi: 10.1056/NEJMc1703047
pubmed: 28514612
Kochi Y, Miyachi H, Tagashira R, et al. Simultaneous development of generalized pustular psoriasis and pemphigoid with multiple autoantibodies in a complete responder of pembrolizumab for lung cancer. J Dermatol. 2023. https://doi.org/10.1111/1346-8138.16832 .
doi: 10.1111/1346-8138.16832
pubmed: 37183481
Hoa S, Laaouad L, Roberts J, et al. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunol Immunother. 2021;70(8):2197–207. https://doi.org/10.1007/s00262-021-02851-5 .
doi: 10.1007/s00262-021-02851-5
pubmed: 33471137
pmcid: 10992076
Vinaixa Aranzazu A, Morillas-Lahuerta V, De Tord MB, Carrascosa Carrillo JM. Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol. 2021. https://doi.org/10.1684/ejd.2021.4087 .
doi: 10.1684/ejd.2021.4087
pubmed: 34463279
pmcid: 8572685
Gleason L, Hunter E, Cohen A, Suriano J, Nikbakht N. Atezolizumab-induced psoriasiform drug eruption successfully treated with ixekizumab: a case report and literature review. Dermatol Online J. 2023. https://doi.org/10.5070/D329160215 .
doi: 10.5070/D329160215
pubmed: 37040912
Kost Y, Mattis D, Muskat A, Amin B, McLellan B. Immune checkpoint inhibitor-induced psoriasiform, spongiotic, and lichenoid dermatitis: a novel clinicopathological pattern. Cureus. 2022;14(8): e28010. https://doi.org/10.7759/cureus.28010 .
doi: 10.7759/cureus.28010
pubmed: 36134105
pmcid: 9470384
Seervai RNH, Heberton M, Cho WC, et al. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. J Cutan Pathol. 2022;49(5):472–81. https://doi.org/10.1111/cup.14185 .
doi: 10.1111/cup.14185
pubmed: 34888886
Nikolaou V, Sibaud V, Fattore D, et al. Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) Group. J Am Acad Dermatol. 2021;84(5):1310–20. https://doi.org/10.1016/j.jaad.2020.08.137 .
doi: 10.1016/j.jaad.2020.08.137
pubmed: 33279646
Glinos GD, Fisher WS, Morr CS, Seminario-Vidal L. Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma. JAAD Case Rep. 2021;11:74–7. https://doi.org/10.1016/j.jdcr.2021.03.029 .
doi: 10.1016/j.jdcr.2021.03.029
pubmed: 33948461
pmcid: 8079959
Gargiulo L, Ibba L, Valenti M, Costanzo A, Narcisi A. Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma. Melanoma Res. 2023;33(2):152–4. https://doi.org/10.1097/CMR.000000000000087 .
doi: 10.1097/CMR.000000000000087
pubmed: 36728879
Mital R, Otto TS, Savu A, et al. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management. Int J Dermatol. 2023;62(8):1020–5. https://doi.org/10.1111/ijd.16714 .
doi: 10.1111/ijd.16714
pubmed: 37203799
Hansen I, Heidrich I, Abeck F, et al. Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab. J Eur Acad Dermatol Venereol. 2023;37(5):e621–3. https://doi.org/10.1111/jdv.18780 .
doi: 10.1111/jdv.18780
pubmed: 36424911
Kim YE, Kim TM, Jo SJ. Histologically-diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: a case report. J Dermatol. 2019;46(12):e464–6. https://doi.org/10.1111/1346-8138.15091 .
doi: 10.1111/1346-8138.15091
pubmed: 31531885
Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57(6):664–9. https://doi.org/10.1111/ijd.13984 .
doi: 10.1111/ijd.13984
pubmed: 29630716
Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79(6):1081–8. https://doi.org/10.1016/j.jaad.2018.07.008 .
doi: 10.1016/j.jaad.2018.07.008
pubmed: 30025829
Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA Dermatol. 2022;58(8):933–41. https://doi.org/10.1001/jamadermatol.2022.1624 .
doi: 10.1001/jamadermatol.2022.1624
Said JT, Talia J, Wei E, et al. Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid. J Am Acad Dermatol. 2023;88(3):670–1. https://doi.org/10.1016/j.jaad.2022.06.1186 .
doi: 10.1016/j.jaad.2022.06.1186
pubmed: 35779636
Ridpath AV, Rzepka PV, Shearer SM, Scrape SR, Olencki TE, Kaffenberger BH. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid. Int J Dermatol. 2018;57(11):1372–4. https://doi.org/10.1111/ijd.13970 .
doi: 10.1111/ijd.13970
pubmed: 29624655
Singer S, Nelson CA, Lian CG, Dewan AK, LeBoeuf NR. Nonbullous pemphigoid secondary to PD-1 inhibition. JAAD Case Rep. 2019;5(10):898–903. https://doi.org/10.1016/j.jdcr.2019.07.015 .
doi: 10.1016/j.jdcr.2019.07.015
pubmed: 31646161
pmcid: 6804458
Sharma P, Barnes M, Nabeel S, LiPera W. Pembrolizumab-induced bullous pemphigoid treated with rituximab. JCO Oncol Pract. 2020;16(11):764–6. https://doi.org/10.1200/JOP.19.00751 .
doi: 10.1200/JOP.19.00751
pubmed: 32716760
Virgen CA, Nguyen TA, Di Raimondo C, et al. Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2020;6(3):195–7. https://doi.org/10.1016/j.jdcr.2020.01.008 .
doi: 10.1016/j.jdcr.2020.01.008
pubmed: 32149176
pmcid: 7033293
Povilaityte E, Gellrich FF, Beissert S, Abraham S, Meier F, Gunther C. Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol. 2021;35(9):e591–3. https://doi.org/10.1111/jdv.17321 .
doi: 10.1111/jdv.17321
pubmed: 33914970
Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol. 2017;153(6):603–5. https://doi.org/10.1001/jamadermatol.2017.0091 .
doi: 10.1001/jamadermatol.2017.0091
pubmed: 28355425
Grimaux X, Delva R, Jadaud E, Croue A. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect. Australas J Dermatol. 2019;60(3):e235–6. https://doi.org/10.1111/ajd.12987 .
doi: 10.1111/ajd.12987
pubmed: 30592031
Kaul S, Wang A, Grushchak S, Albrecht J. Pembrolizumab-induced reactivation of bullous pemphigoid. Int J Dermatol. 2021;60(6):757–8. https://doi.org/10.1111/ijd.15366 .
doi: 10.1111/ijd.15366
pubmed: 33615441
Morris LM, Lewis HA, Cornelius LA, Chen DY, Rosman IS. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: a case series. J Cutan Pathol. 2020;47(8):742–6. https://doi.org/10.1111/cup.13687 .
doi: 10.1111/cup.13687
pubmed: 32196722
Wesolow JT, Jalali S, Clark LD. A rare case of bullous pemphigoid secondary to checkpoint inhibitor immunotherapy: a tense situation. Cureus. 2021;13(7): e16169. https://doi.org/10.7759/cureus.16169 .
doi: 10.7759/cureus.16169
pubmed: 34367779
pmcid: 8336291
Sadik CD, Langan EA, Gutzmer R, et al. Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers. Front Immunol. 2020;11: 588582. https://doi.org/10.3389/fimmu.2020.588582 .
doi: 10.3389/fimmu.2020.588582
pubmed: 33708189
Schauer F, Rafei-Shamsabadi D, Mai S, et al. Hemidesmosomal reactivity and treatment recommendations in immune checkpoint inhibitor-induced bullous pemphigoid: a retrospective, monocentric study. Front Immunol. 2022;13: 953546. https://doi.org/10.3389/fimmu.2022.953546 .
doi: 10.3389/fimmu.2022.953546
pubmed: 35936009
pmcid: 9355658
Brown AM, Masterson W, Lo J, Patel AB. Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review. Dermatitis. 2021. https://doi.org/10.1097/DER.0000000000000776 .
doi: 10.1097/DER.0000000000000776
Yun JSW, Chan OB, Goh M, McCormack CJ. Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a case series of 13 patients. Australas J Dermatol. 2023;64(1):131–7. https://doi.org/10.1111/ajd.13960 .
doi: 10.1111/ajd.13960
pubmed: 36514287
Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep. 2016;2(6):442–4. https://doi.org/10.1016/j.jdcr.2016.05.009 .
doi: 10.1016/j.jdcr.2016.05.009
pubmed: 27981213
pmcid: 5144742
Choi SH, Chung KB, Kim DY. Inhibition of transforming growth factor beta and immune checkpoints induces a distinctively distributed, severe bullous pemphigoid. Acta Derm Venereol. 2021;101(6): adv00489. https://doi.org/10.2340/00015555-3853 .
doi: 10.2340/00015555-3853
pubmed: 34159393
Klepper EM, Robinson HN. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature. Dermatol Online J. 2021;27(9). doi: https://doi.org/10.5070/D327955136 .
Bruni M, Moar A, Schena D, Girolomoni G. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab. Dermatol Online J. 2022. https://doi.org/10.5070/D328257396 .
doi: 10.5070/D328257396
pubmed: 36809097
Pop SR, Strock D, Smith RJ. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report. Dermatol Ther. 2022;35(8): e15623. https://doi.org/10.1111/dth.15623 .
doi: 10.1111/dth.15623
pubmed: 35669992
pmcid: 9539473
Khazaeli M, Grover R, Pei S. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma. J Cutan Pathol. 2023;50(6):520–3. https://doi.org/10.1111/cup.14383 .
doi: 10.1111/cup.14383
pubmed: 36601731
Shipman WD, Singh K, Cohen JM, Leventhal JS, Damsky WD, Tomayko MM. Immune checkpoint inhibitor-induced bullous pemphigoid skin has elevated interleukin-4 and interleukin-13 expression and responds to IL-4R inhibitionImmune checkpoint inhibitor-induced bullous pemphigoid skin has elevated interleukin-4 and interleukin-13 expression and responds to IL-4R inhibition. J Invest Dermatol. 2022;142(8):S5.
doi: 10.1016/j.jid.2022.05.084
Mihailescu ML, Brockstein BE, Desai N, Waldinger J. Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid. CPC Case Rep. 2020;2:100031. https://doi.org/10.1016/j.cpccr.2020.100031 .
Cardona AF, Ruiz-Patino A, Zatarain-Barron ZL, et al. Refractory bullous pemphigoid in a patient with metastatic lung adenocarcinoma treated with pembrolizumab. Case Rep Oncol. 2021;14(1):386–90. https://doi.org/10.1159/000514144 .
doi: 10.1159/000514144
pubmed: 33776733
pmcid: 7983585
Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series. J Am Acad Dermatol. 2020;83(5):1475–7. https://doi.org/10.1016/j.jaad.2020.03.029 .
doi: 10.1016/j.jaad.2020.03.029
pubmed: 32199891
Cai ZR, Lecours J, Adam JP, et al. Toxic epidermal necrolysis associated with pembrolizumab. J Oncol Pharm Pract. 2020;26(5):1259–65. https://doi.org/10.1177/1078155219890659 .
doi: 10.1177/1078155219890659
pubmed: 31810421
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990–7. https://doi.org/10.1016/j.jaad.2018.10.062 .
doi: 10.1016/j.jaad.2018.10.062
pubmed: 30399387
Zhang L, Wu Z. Adalimumab for sintilimab-induced toxic epidermal necrolysis in a patient with metastatic gastric malignancy: a case report and literature review. Clin Cosmet Investig Dermatol. 2023;16:457–61. https://doi.org/10.2147/CCID.S401286 .
doi: 10.2147/CCID.S401286
pubmed: 36846442
pmcid: 9951597
Chen PY, Li ZY, Cai SQ. Case report: cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental adalimumab. Front Immunol. 2023;14:1188523. https://doi.org/10.3389/fimmu.2023.1188523 .
doi: 10.3389/fimmu.2023.1188523
pubmed: 37600791
pmcid: 10435079
Meledathu S, Gordon M, Thornton M, Ashinoff R. Management of Stevens-Johnson syndrome/toxic epidermal necrolysis: a case report and literature review. J Drugs Dermatol. 2023;22(11):e24–8. https://doi.org/10.36849/JDD.6999 .
doi: 10.36849/JDD.6999
pubmed: 37943271
Kian W, Zemel M, Elobra F, et al. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. Anticancer Drugs. 2022;33(1):e738–40. https://doi.org/10.1097/CAD.0000000000001162 .
doi: 10.1097/CAD.0000000000001162
pubmed: 34321417
Sandhu M, Kc B, Bhandari J, Gambhir HS, Farah R. Pembrolizumab-associated Stevens-Johnson syndrome in a patient with metastatic non-small cell lung cancer: a case report. Cureus. 2023;15(7): e41439. https://doi.org/10.7759/cureus.41439 .
doi: 10.7759/cureus.41439
pubmed: 37546048
pmcid: 10403812
Borg L, Buhagiar M, La Ferla E, Pisani D, Said J, Boffa MJ. Pembrolizumab-induced toxic epidermal necrolysis. Case Rep Oncol. 2022;15(3):887–93. https://doi.org/10.1159/000526931 .
doi: 10.1159/000526931
pubmed: 36825108
pmcid: 9941788
Ingen-Housz-Oro S, Milpied B, Badrignans M, et al. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Res. 2022;32(3):205–10. https://doi.org/10.1097/CMR.0000000000000819 .
doi: 10.1097/CMR.0000000000000819
pubmed: 35377864
pmcid: 9377568
Yang Y, Li J, Till BG, et al. Toxic epidermal necrolysis-like reaction following combination therapy with camrelizumab and apatinib for advanced gallbladder carcinoma. Front Oncol 2021;11:728523. https://doi.org/10.3389/fonc.2021.728523 .
Nayar N, Briscoe K, Fernandez PP. Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with opilimumab refractory metastatic melanoma. J Immunother. 2016;39(3):149–52. https://doi.org/10.1097/CJI.0000000000000112 .
doi: 10.1097/CJI.0000000000000112
pubmed: 26938948
Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381–4. https://doi.org/10.1111/cup.12876 .
doi: 10.1111/cup.12876
pubmed: 28000240
Ahmad M, Murphy MJ, Damsky W, Leventhal J. Dupilumab-induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. Int J Dermatol. 2022;62(8):e42–6. https://doi.org/10.1111/ijd.16538 .
doi: 10.1111/ijd.16538
Kuo AM, Gu S, Stoll J, et al. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. 2023;11(6): e007324. https://doi.org/10.1136/jitc-2023-007324 .
doi: 10.1136/jitc-2023-007324
pubmed: 37270183
pmcid: 10255229
Hibler BP, Markova A. Treatment of severe cutaneous adverse reaction with tocilizumab. Br J Dermatol. 2020;183(4):785–7. https://doi.org/10.1111/bjd.19129 .
doi: 10.1111/bjd.19129
pubmed: 32291751
pmcid: 7541614
Park JJ, Park E, Damsky WE, Vesely MD. Pembrolizumab-induced lichenoid dermatitis treated with dupilumab. JAAD Case Rep. 2023;37:13–5. https://doi.org/10.1016/j.jdcr.2023.05.004 .
doi: 10.1016/j.jdcr.2023.05.004
pubmed: 37332364
pmcid: 10275729
Alamon-Reig F, Bosch-Amate X, Giavedoni P, et al. Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: a retrospective cohort from the European Task Force of Dermatology for Cancer patients. J Am Acad Dermatol. 2024;90(2):429–32. https://doi.org/10.1016/j.jaad.2023.10.012 .
doi: 10.1016/j.jaad.2023.10.012
pubmed: 37844688
Blaise M, Cardot-Leccia N, Seitz-Polski B, et al. Tocilizumab for corticosteroid-refractory immune checkpoint inhibitor-induced generalized morphea. JAMA Dermatol. 2023;159(1):112–4. https://doi.org/10.1001/jamadermatol.2022.5146] .
doi: 10.1001/jamadermatol.2022.5146]
pubmed: 36449277
Herrscher H, Tomasic G, Castro GA. Generalised morphea induced by pembrolizumab. Eur J Cancer. 2019;116:178–81. https://doi.org/10.1016/j.ejca.2019.05.018 .
doi: 10.1016/j.ejca.2019.05.018
pubmed: 31202088
DeMaio A, Hashemi KB, Avery A, Metcalf JS, Winterfield LS. A case of nivolumab-induced scleroderma-like syndrome successfully treated with intravenous immunoglobulin. JAAD Case Rep. 2023;31:76–9. https://doi.org/10.1016/j.jdcr.2022.06.007 .
doi: 10.1016/j.jdcr.2022.06.007
pubmed: 36545488
Barbosa NS, Wetter DA, Wieland CN, Shenoy NK, Markovic SN, Thanarajasingam U. Scleroderma induced by pembrolizumab: a case series. Mayo Clin Proc. 2017;92(7):1158–63. https://doi.org/10.1016/j.mayocp.2017.03.016 .
doi: 10.1016/j.mayocp.2017.03.016
pubmed: 28599746
Shelton E, Doolittle C, Shinohara MM, Thompson JA, Moshiri AS. Can’t handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab. JAAD Case Rep. 2022;22:31–3. https://doi.org/10.1016/j.jdcr.2022.01.029 .
doi: 10.1016/j.jdcr.2022.01.029
pubmed: 35274032
pmcid: 8904183
Panou E, Stavridi F, Nikolaou C, Stratigos A, Nikolaou V. Dupilumab for the treatment of immune checkpoint blockers’ induced pruritus. J Eur Acad Dermatol Venereol. 2023;37(12):e1475–6. https://doi.org/10.1111/jdv.19369 .
doi: 10.1111/jdv.19369
pubmed: 37471503
Utsunomiya A, Oyama N, Iino S, et al. A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: possible implication of synergistic and/or complementary immunomodulatory effects. Case Rep Dermatol. 2018;10(1):1–6. https://doi.org/10.1159/000485910 .
doi: 10.1159/000485910
pubmed: 29515387
pmcid: 5836162
Belzer A, Pach JJ, Valido K, Leventhal JS. The impact of dermatologic adverse events on the quality of life of oncology patients: a review of the literature. Am J Clin Dermatol. 2024. https://doi.org/10.1007/s40257-024-00847-2 .
doi: 10.1007/s40257-024-00847-2
pubmed: 38366030
Schulz TU, Zierold S, Sachse MM, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients’ health-related quality of life. Eur J Cancer. 2022;176:88–99. https://doi.org/10.1016/j.ejca.2022.08.029 .
doi: 10.1016/j.ejca.2022.08.029
pubmed: 36198246
Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25(5):1713–39. https://doi.org/10.1007/s00520-017-3629-4 .
doi: 10.1007/s00520-017-3629-4
pubmed: 28224235
Phillips GS, Freites-Martinez A, Wu J, et al. Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics. JAMA Dermatol. 2019;155(2):249–51. https://doi.org/10.1001/jamadermatol.2018.4560 .
doi: 10.1001/jamadermatol.2018.4560
pubmed: 30540342
Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279–86. https://doi.org/10.1111/1346-8138.14096 .
doi: 10.1111/1346-8138.14096
pubmed: 29226369
Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. https://doi.org/10.3390/ijms21051690 .
doi: 10.3390/ijms21051690
pubmed: 32121574
pmcid: 7084606
Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020;33(3):e00035-e119. https://doi.org/10.1128/CMR.00035-19 .
doi: 10.1128/CMR.00035-19
pubmed: 32522746
pmcid: 7289788
Kang JH, Bluestone JA, Young A. Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines. Trends Immunol. 2021;42(4):293–311. https://doi.org/10.1016/j.it.2021.02.006 .
doi: 10.1016/j.it.2021.02.006
pubmed: 33714688
Shipman WD, Singh K, Cohen JM, Leventhal J, Damsky W, Tomayko MM. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. Br J Dermatol. 2023;189(3):339–41. https://doi.org/10.1093/bjd/ljad149 .
doi: 10.1093/bjd/ljad149
pubmed: 37140007
pmcid: 10947518
Shi J, Song X, Traub B, Luxenhofer M, Kornmann M. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22062998 .
doi: 10.3390/ijms22062998
pubmed: 35008672
pmcid: 8745729
Verheijden RJ, May AM, Blank CU, et al. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res. 2020;26(9):2268–74. https://doi.org/10.1158/1078-0432.CCR-19-3322 .
doi: 10.1158/1078-0432.CCR-19-3322
pubmed: 31988197
Fattore D, Annunziata MC, Panariello L, Marasca C, Fabbrocini G. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. Eur J Cancer. 2019;110:107–9. https://doi.org/10.1016/j.ejca.2019.01.010 .
doi: 10.1016/j.ejca.2019.01.010
pubmed: 30785013
Apalla Z, Psarakis E, Lallas A, Koukouthaki A, Fassas A, Smaragdi M. Psoriasis in patients with active lung cancer: is apremilast a safe option? Dermatol Pract Concept. 2019;9(4):300–1. https://doi.org/10.5826/dpc.0904a11 .
doi: 10.5826/dpc.0904a11
pubmed: 31723466
pmcid: 6830556
Gresham LM, Kirchhof MG. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: a case report. SAGE Open Med Case Rep. 2023. https://doi.org/10.1177/2050313X231160926 .
doi: 10.1177/2050313X231160926
pubmed: 36968984
pmcid: 10034281